Skip to main content
. Author manuscript; available in PMC: 2016 Aug 1.
Published in final edited form as: Trends Biotechnol. 2015 Jun 16;33(8):449–461. doi: 10.1016/j.tibtech.2015.05.001

Table 1.

Advances in adoptive T cell therapy

Institutions Date Technology Clinical Trials Details Ref
University of Pennsylvania/Novartisa August, 2012 CTL019 NCT02167360, NCT02228096, NCT02030834, NCT01626495, NCT01029366 CD19-specific CAR for B Cell Acute Lymphoblastic Leukemia (B-ALL) [32]
Juno Therapeuticsb,c December, 2013 JCAR015 NCT01044069, NCT01840566 CD19-specific CAR for B-ALL and non-Hodgkin lymphoma (NHL) [30, 109–111]
JCAR017 NCT02028455 CD19-specific CAR for leukemia
JCAR014 NCT01865617 CD19-specific CAR for chronic lymphocytic leukemia, NHL, ALL
JTCR016 NCT01640301, NCT00052520 WT1-specific TCR for leukemia, myelodysplastic syndrome

Exploration of other targetsd
Preclinical		 L1CAM: neuroblastoma, glioblastoma, lung cancer, pancreatic cancer, and ovarian cancer
MUC-16: ovarian cancer
ROR-1: lung cancer, triple negative breast cancer, pancreatic cancer, prostate cancer, ALL
Juno/Opus Bio, Inc./National Cancer Institute (NCI)e December, 2014 CD22-CAR NCT02315612, NCT02159495 Leukemia, lymphoma
Celgene/Bluebird Bio/Baylorf March, 2013 Hematological/Solid Tumors
Kite Pharmaceuticals/National Cancer Instituteg,h October, 2012 CD19-CAR NCT00924326, NCT02348216 B-cell leukemia, lymphoma [112, 113]
EGFRvlll-CAR NCT01454596 Glioblastoma [114, 115]
NY-ESO-1 TCR NCT01967823 ESO-expressing tumors
HPV-16E6 TCR NCT0228081 Cervical/Head & Neck Cancer
HPV-16E7 TCR Cervical/Head & Neck Cancer
MAGE A3 TCR NCT02111850 MAGE-A3-DP4-expressing tumors
SSX2 TCR NCT02153905 MAGE-A3-expressing tumors, metastatic melanoma
Kite Pharmaceuticals/Amgen January, 2015 Exploration of other targets Preclinical Hematologic cancers and solid tumors
MD Anderson/Ziopharm Oncology/lntrexonj January, 2015 RheoSwitch Therapeutic System Preclinical Switches for control of dynamic range, spatial expression, and temporal expression
Non-Viral Integration Sleeping Beauty transposon system for integration of CARs in T cells
Universal donor Preclinical
CD19-specific CAR NCT01497184, NCT01653717 Leukemia, lymphoma
Cellectis/Ohio State Universityk January, 2015 CS1-specific CAR Preclinical Multiple myeloma
Pfizer/Cellectisl June, 2014 Working on several targets for CAR therapy
GlaxoSmithKline/Adaptimmunem June, 2014 NY-ESO-1 TCR NCT01350401, NCT01567891, NCT01892293 Multiple myeloma, melanoma, sarcoma, and ovarian cancer
Advanced Designs for Adoptive T Cell Therapy
Servier/Cellectisn February, 2014 UCART19 Filing for clinical trial authorization Off-the shelf T cell for leukemia
Unum Therapeuticso 2014 ACTR+anti-CD20 antibody NCT02315118 Leukemia, Non-Hodgkin’s lymphoma [51]
Bellicum Pharmaceuticals 2011 GoCAR-T Preclinical Prostate stem cell antigen-expressing solid tumors [50]
Bellicum Pharmaceuticals/Texas Children’s Hospital/Baylor College of Medicine 2011 CaspaCIDe NCT01494103 Graft-versus-host disease [67]
Bluebird bio (Acquisition of Pregenen)p June, 2014 Homing endonucleases, MegaTALEs
Novartis/lntelliaq January, 2015 CRISPR